Call us:

Global Proteomic Quantification Service

The label-free method is a good alternative for protein quantification because of the higher mass accuracy and faster scanning speed on mass spectrometers, the significant advances in computational methods and software for data processing, and its lower cost compared to labeled methods. For a comprehensive characterization of the proteome, an analytical platform capable of quantifying protein abundance, identifying post-translational modifications and revealing members of protein complexes at the whole-system level is necessary. Relying on mass spectrometry, coupled with sample fractionation and automated data analysis techniques, we provide such a versatile and powerful data independent acquisition (DIA) platform.

Our Proteomic Quantification Service

Using a high-resolution, fast-sampling mass spectrometer operating in a data-independent mode, we can identify and quantify unknown proteins on a large scale from complex biological samples (such as cultures, tissues, or cells in plasma). Our Discovery Proteomics Platform contains three major data independent quantification strategies that can quantify up to 9,000 proteins per sample under different conditions.

DIA is a high-throughput proteomics research tool that is particularly suitable for clinical biomarker studies. Among the existing DIA technologies, the SWATH (Sequential window acquisition of all theoretical spectra) strategy has been more widely used. DIA can detect all precursor ions, but the selectivity is 5-10 times lower than that of DDA or MRM. The msxDIA technology can increase the selectivity of the precursor ion by 5 times and reduce the complexity of data processing. Compared with the traditional DIA data processing mode, its advantage is that researchers do not need to collect DDA data to build a spectral library. Our Unique Super Reaction Monitoring (SRM™) platform combines Data-Dependent Analysis (DDA) and DIA technologies to obtain data before each analysis. Shortcomings of DDA and selected reaction monitoring (SRM) in terms of depth and width that have limited researchers from examining complex biological systems are addressed by SRM™.

There is no doubt that DIA, which overcomes the randomness of DDA and the low-throughput of MRM, will become a powerful tool for proteome quantification and protein biomarker discovery and verification. However, any technology is not perfect, and it is necessary to choose the applicable quantitative technology according to the actual situation. We will choose the most suitable analysis method for you according to your sample, experimental purpose, etc.

Advantages and limitations of DDA-MS in comparison to DIA-MSAdvantages and limitations of DDA-MS in comparison to DIA-MS[1]

Our Protein Quantification Services Include:


Sample Requirements:

Based on our special protein extraction technology, we can quickly extract proteins from various samples and design personalized experimental schemes according to different experimental purposes. Specific requirements are as follows:

Sample TypeProtein# of CellsAnimal TissuePlant TissueBloodUrineSerumMicrobes
Quantify100 ug1×107 cells1 g200 mg1 mL2 mL0.2-0.5 mLDry weighed: 200 mg



LC-MS/MS Report


  1. Lukas Krasny. Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology. Mol. Omics, 2021, 17, 29-42.
* For Research Use Only. Not for use in the treatment or diagnosis of disease.

Online Inquiry


Specializing in proteomics, Creative Proteomics offers cutting-edge protein analysis services. Our distinctive approach revolves around harnessing the power of DIA technology, enabling us to deliver precise and comprehensive insights that drive advancements in research and industry.

  • USA
  • Tel:
  • Fax:
  • Email:
  • Germany
Copyright © 2024 Creative Proteomics. All rights reserved.